SPE Capital exits Moroccan pharma company
Private equity firm SPE Capital has announced the sale of Amanys Pharma to Laprophan, a pharmaceutical company in Morocco, subject to obtaining the required regulatory approvals.
For the best experience and to access our Connect industry chat platform, download the Africa Private Equity News app: Android | iOS
Private equity firm SPE Capital has announced the sale of Amanys Pharma to Laprophan, a pharmaceutical company in Morocco, subject to obtaining the required regulatory approvals. This transaction constitutes the second exit for SPE AIF, the $260 million African-focused fund managed by SPE Capital and which reached final close December 2020.
Laprophan and Amanys aim to form a diversified pharmaceutical group in Morocco and Africa, built around specialised and complementary businesses.
Farid Bennis, CEO of Laprophan stated, “I am convinced that this coming together of two pharmaceutical players with real synergies will serve the interests of patients in Morocco and more broadly in Africa.”
Mly Younous Elalamy, general manager of Amanys said, “We are delighted with this partnership that will ensure the continuation of our group’s development, while taking advantage of the industrial and commercial complementarities that exist between Amanys and Laprophan.”
Nabil Triki, managing partner and CEO of SPE Capital said, “I am proud of the company’s achievements, both strategic and industrial. We are happy to have supported Amanys and its management team in their ambitious development plan.”
SPE Capital was assisted by DLA Piper (legal advisor), and KPMG (financial advisor). Laprophan was advised by ASAFO & Co. (legal counsel) and Deloitte (financial advisor).
* Subscribe to Africa Private Equity News’ monthly Dealmaker’s Log for a database of the reported investment deals, exits and fundraising closes. Click here for more information.